ONCIN.OL Oncoinvent ASA
- Market cap
- NOK 416M
- P/E
- -
- P/B
- 4.97x
- ROE
- -106.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ONCIN.OL undervalued?
Graham numberThe Graham number of Oncoinvent ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncoinvent ASA fundamental analysis
No fundamental analysis for Oncoinvent ASA yet.
Oncoinvent ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Full company profileOncoinvent ASA financial statements
Oncoinvent ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 774K | 389K | 354K | 848K | 28.1M |
| Gross Profit | - | -5.70M | -5.07M | -2.59M | - |
| Operating Income | -314M | -306M | -192M | -151M | -158M |
| EBITDA | - | -301M | -190M | -126M | -144M |
| Net Income | -309M | -302M | -190M | -139M | -155M |
| EPS | -194 | -2,505 | -454 | -1.51 | -35 |
| Balance Sheet | |||||
| Total Assets | 450M | 167M | 174M | 171M | 205M |
| Total Liabilities | 65.8M | 78.2M | 46.9M | 62.7M | 58.6M |
| Shareholders' Equity | 384M | 88.5M | 127M | 108M | 146M |
| Cash & Short-term Investments | 436M | 151M | 156M | 140M | 178M |
| Cash Flow | |||||
| Operating Cash Flow | -303M | -288M | -138M | -153M | -131M |
| Capital Expenditure | 0.00 | 3.98M | 26.8M | 1.80M | 119K |
| Free Cash Flow | -303M | -288M | -165M | -153M | -131M |
| Ratios | |||||
| ROE | -80.5% | -341.4% | -149.4% | -128.6% | -106.0% |
| ROA | -68.7% | -181.2% | -109.2% | -81.4% | -75.7% |
| Net Profit Margin | -39,969.5% | -77,666.3% | -53,785.6% | -16,424.8% | -552.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oncoinvent ASA dividends
Oncoinvent ASA has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on Jan 19, 2026.
Who owns Oncoinvent ASA
- Insiders 22.38%
- Institutions 35.27%
- Public & others 42.34%
- Shares outstanding 6.13M
- Free float 3.26M
Oncoinvent ASA company profile
- Company name
- Oncoinvent ASA
- Ticker
- ONCIN.OL
- ISIN
- NO0013251173
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 42
- Fiscal year end
- December
- Address
- Gullhaugveien 7, Oslo, Norway, 0484
- Phone
- 47 22 18 33 05
- Website
- oncoinvent.com
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Oncoinvent ASA management
9- Mr. Oystein Soug M.ScChief Executive Officer · born 1969
- Ms. Gro Elisabeth HjellumChief Operating Officer
- Ms. Kristine LofthusChief Production Officer
- Ms. Anne Cecile AlvikHead of Quality Assurance & Employee Representative Director
- Dr. Anne-Kirsti Aksnes Ph.D.Chief Clinical Officer
- Dr. Ramzi Amri M.D., Ph.D.Chief Financial Officer
- Dr. Sara WestrømChief Scientific Officer
- Ms. Kaja Tunhovd JohansenHead of Quality Control
- Dr. Zuzana Jirakova Trnkova M.D., Ph.D.Chief Medical Officer